<DOC>
	<DOCNO>NCT01770795</DOCNO>
	<brief_summary>To evaluate efficacy safety Genexol-PM ( CrEL-free polymeric micelle formulate paclitaxel ) gemcitabine untreated metastatic NSCLC patient</brief_summary>
	<brief_title>A Phase II Trial Genexol-PM Gemcitabine Patients With Advanced Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>age 18 histologically cytologically confirmted nonsmall cell lung cancer stage IIIb pleural effusion stage IV ECOG PS 02 least one measurable lesion expect life span 3 month normal bone marrow , liver , renal function prior chemotherapy radiotherapy except whole brain radiotherapy symptomatic brain metastasis 6 month last adjuvant chemotherapy active infection severe comorbitidies pregnant lactate woman invasive malignancy poorly control symptomatic brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>genexol-PM</keyword>
	<keyword>paclitaxel</keyword>
</DOC>